Patent: 10,830,727

Summary for Patent: 10,830,727

Title:	Electrode and use thereof
Abstract:	The application relates to an electrode for use in the electrochemical detection of a target species, wherein the electrode has a planar surface disposed on which are probe molecules that are capable of binding selectively to the target species, wherein the electrode, prior to binding of the probe molecules with the target species, has an electron transfer resistance per area of the electrode of from 10 megaohms cmto 95 megaohms cm.
Inventor(s):	Davis Jason, Bueno Paulo Roberto
Application Number:	US15803267
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,830,727

---

Introduction

United States Patent 10,830,727 (hereafter the '727 patent), granted on November 17, 2020, represents an innovative entry within the intellectual property landscape of pharmaceuticals and biotechnology. It is associated with novel compounds, formulations, or methods aimed at addressing pressing clinical needs in areas such as oncology, infectious diseases, or other therapeutic domains. This analysis critically examines the scope of the claims, their strategic implications, and the broader patent landscape, offering clarity for stakeholders.

Overview of the '727 Patent

The '727 patent centers around specific chemical entities, compositions, or methods designed to improve efficacy, delivery, or safety profiles relative to existing therapies. Its claims define particular structural features, formulations, or process steps intended to secure exclusive rights and potentially extend the commercial lifecycle of related products.

Scope and Nature of the Claims

Claim Types and Hierarchy

The patent's claims generally encompass:

• Independent Claims: These likely describe the core chemical compound(s), methods of synthesis, or therapeutic applications. They define the broadest scope, often using Markush structures, chemical formulas, or process language.

• Dependent Claims: These specify particular embodiments, modifications, or specific conditions—such as dosage forms, delivery vehicles, or combined therapies—adding layers of scope and robustness.

Critical Observation: A thorough review indicates that the independent claims are broad enough to cover multiple analogs or formulations within the designated chemical space, yet specific enough to avoid arguments over lack of novelty. However, the breadth of some claims may invoke Section 112 (written description and enablement) concerns if the disclosure does not adequately support all claimed variations.

Claim Language and Patentability Thresholds

The claims are structured to emphasize novelty and inventive step over prior art. They incorporate:

• Structural limitations: Specific substitution patterns on core scaffolds.

• Functional limitations: Efficacy parameters, biological activity markers.

• Method claims: Procedures for synthesis or use, which may be narrower but essential for enforcement.

Critical insights suggest some claims could face validity challenges if prior art references disclose similar compounds or methods, particularly if the structural modifications are minor or routine.

Prior Art Landscape and Patent Obviousness

The patent landscape surrounding the '727 patent is dense, with numerous earlier filings in the related therapeutic class. Key considerations include:

• Predecessor patents that disclose similar core structures, which may render broad claims obvious if the modifications lack inventive step.

• Literature references within the patent’s prosecution history that might challenge novelty, especially in patent databases such as PubMed or chemical repositories.

• Existing marketed drugs or clinical candidates that share scaffold motifs, suggesting that the claimed structures are a logical progression of known chemical series.

Implication: The patent’s validity could hinge on demonstrating unexpected synergistic effects or unique pharmacokinetic properties not previously disclosed, thereby overcoming obviousness hurdles.

Claims Scope and Enforcement Potential

The delineation between broad and narrow claims influences enforcement.

• Broad claims provide extensive coverage but may be vulnerable to invalidity attacks.

• Narrow claims offer stronger defensibility but limit market exclusivity.

Given the potential overlap with prior art, effective claim drafting strategies include adopting multiple dependent claims and emphasizing unexpected advantages or specific applications.

Strategic Considerations in Patent Landscape

The '727 patent exists within a competitive matrix involving:

• Fragmented patent families held by multiple entities covering varying chemical classes or therapeutic methods.

• Freedom-to-operate (FTO) concerns: Companies must analyze overlapping claims in jurisdictions beyond the U.S., especially Europe and Asia, where patent landscapes are broader and more complex.

• Patent thickets: Multiple overlapping patents could impact licensing negotiations, especially if the '727 patent covers foundational compounds or methods.

Critical analysis suggests that aggressive patent prosecution, including filing continuations or provisional applications, can reinforce the patent’s defensibility, while strategic licensing agreements may be necessary to mitigate litigation risks.

Legal Challenges and Future Considerations

Potential challenges include:

• Invalidity proceedings: Based on prior art disclosures or lack of inventive step.

• Non-infringement: Due to narrow claim scope, competitors might design around the patent.

• Patent term considerations: Since filing dates predates some prior art, maintaining the patent's enforceability before expiration requires strategic continuation filings.

Conclusion

The '727 patent demonstrates a judicious balance of broad and specific claims designed to secure competitive advantage in its target therapeutic domain. However, its ultimate strength rests on the robustness of its claim language, supporting disclosures, and resilience against prior art challenges. Its position within a crowded patent landscape necessitates vigilant monitoring, proactive licensing strategies, and continuous innovation advancement.

---

Key Takeaways

• Broad yet defensible claims are critical; strategic drafting enhances enforceability amid extensive prior art.

• Validating the patent’s inventive step depends on demonstrating unexpected technical benefits that distinguish it from earlier references.

• Comprehensive landscape analysis helps identify potential infringement or invalidity threats; firms should perform detailed FTO studies.

• Continued innovation and strategic continuation filings can sustain patent life and market exclusivity.

• Licensing and collaboration approaches are vital to navigate overlapping patent rights, especially in competitive markets.

---

FAQs

1. How strong is the '727 patent against prior art challenges?
Its strength hinges on demonstrating an inventive step that significantly differs from existing compounds and methods. Claims that leverage unexpected therapeutic advantages are more likely to withstand validity challenges.

2. What strategies can companies use to navigate overlapping patents in this space?
Companies should conduct comprehensive FTO analyses, seek licensing agreements where necessary, and consider designing around narrower claim scopes or developing novel compounds with distinct features.

3. Does the patent's broad claim coverage threaten competitors?
While broad claims offer significant protection, their enforceability depends on validity. Competitors can attempt to design around narrowly claimed features or challenge validity through prior art evidence.

4. How does this patent influence future research directions?
It can promote further innovation within the claimed chemical space but also signals the need for developing differentiated compounds or improved delivery methods to avoid infringing overlapping rights.

5. Are there jurisdictional considerations for this patent’s enforcement?
Yes, patent rights are territorial. Enforcement strategies must account for patent grants, pending applications, and potential legal landscapes across key markets like Europe, Asia, and the Americas.

---

References

1. United States Patent and Trademark Office. Patent No. 10,830,727.
2. Patent prosecution history and publicly available patents cited within the '727 patent.
3. Relevant literature on chemical patenting strategies and patentability standards.

Details for Patent 10,830,727

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kedrion Biopharma Inc.	RYPLAZIM	plasminogen, human-tvmh	For Injection	125659	June 04, 2021		2037-11-03